• Main page
• About the journal
• Editorial board
• Subscription
• Information for contributors
• Editorial and Peer Review
• Issues archive
• Authors
• Articles
  • By alphabet
  • By category
• Blogs and comments

The journal is included into The list of leading scientific periodicals.

The journal is included into VINITI database and is registered in Electronic scientific library.

The journal is indexed by SCOPUS, Ulrich's International Periodicals Directory.

EBSCO

https://doi.org/10.14300/mnnc.2021.16044

Anticataleptic activity of 2-substituted derivatives of 3(H)-quinazolin-4-one

[Experimental medicine]
Mikael Manvelyan; Eleonora Manvelyan; Vladimir Baturin; Pavel Viktorovich Shamik;

The anticataleptic effect of 2-substituted derivatives of 3(H)-quinazolin-4-one in male rats was examined using a haloperidol catalepsy test. Compounds I, II, III, IV, V, VI, and VII (laboratory codes) were administered at a dose of 0.2 of the molecular weight in mg/kg. Catalepsy was induced by administration of haloperidol (1 mg/kg). Control animals were injected with a neuroleptic solvent. In male rats, compounds IV and V limited the severity of motor disorders and showed anticataleptic activity, suggesting their possible use as antiparkinsonian treatments.

Download

References:
1. Kalia L. V., Lang A. E. Parkinson’s disease. The Lancet. 2015;386:896912. https://doi.org/10.1016/S0140-6736(14)61393-3
2. Dinda B., Dinda M., Kulsi G., Chakraborty A., Dinda S. Therapeutic potentials of plant iridoids in Alzheimer’s and Parkinson’s diseases: A review. Eur. J. Med. Chem. 2019;169:185199. https://doi.org/10.1016/j.ejmech.2019.03.009
3. Carrarini C., Russo M., Dono F., Pietro M. D., Rispoli M. G. [et al.] A Stage-Based Approach to Therapy in Parkinson’s Disease. Biomolecules. 2019;9(8):388. https://doi.org/10.3390/biom9080388
4. Oertel W., Schulz J. B. Current and experimental treatments of Parkinson disease: A guide for neuroscientists. J. Neurochem. 2016;139(1):325337. https://doi.org/10.1111/jnc.13750
5. Kodonidi I. P., Oganesyan E. T., Ryabukhin Yu. I., Smirnova L. P., Lysenko T. A. [et al.] Synthesis and biological activity of 1,4-dihydro-4-oxopyrimidine n-heterocyclic derivatives. Voprosy biologicheskoy, meditsinskoy i farmatsevticheskoy khimii. – Questions of biological, medical and pharmaceutical chemistry. 2012;4:1926.
6. Manvelyan Е. А., Manvelyan M. М., Codоnidi I. P., Oganesyan E. T. Аnalgesic activity of new derivatives of quinazolinone-4. Medical News of North Caucasus. 2017;12(3):307311. https://doi.org/10.14300/mnnc.2017.12089
7. Manvelyan E. A., Manvelyan M. M., Oganesyan E. T., Kodonidi I. P. Antihypoxant effect of hydroxy and methoxyphenyl derivatives of quinazolin-4(3H)-one. Eksperimentalnaya i klinicheskaya farmakologiya. – Experimental and clinical pharmacology. 2019;82(4):1619. https://doi.org/10.30906/0869-2092-2019-82-4-16-19
8. Voronina T. A., Valdman Ye. A., Nerobkova L. N., Kapitsa I. G. Metodicheskiye rekomendatsii po doklinicheskomu izucheniyu lekarstvennykh sredstv s protivoparkinsonicheskoy aktivnostyu. Rukovodstvo po provedeniyu doklinicheskikh issledovany lekarstvennykh sredstv. Pod obsh. red. A. N. Mironova. M.: «Grif i K», 2012.
9. Bricker B., Sampson D., Ablordeppey S. Y. Evaluation of the potential of antipsychotic agents to induce catalepsy in rats: assessment of a new, commercially available, semi-automated instrument. Pharmacol. Biochem. Behav. 2014;120:109116. https://doi.org/10.1016/j.pbb.2014.02.013
10. Luciani K. R., Frie J. A., Khokhar J. Y. An Open Source Automated Bar Test for Measuring Catalepsy in Rats. Eneuro. 2020;7(3):0488-19.2020. https://doi.org/10.1523/ENEURO.0488-19.2020
11. Manvelyan E. A., Baturin V. A., Kolodychuk Ye. V. Gendernye razlichiya v effektivnosti psikhotropnykh i kardiotropnykh lekarstvennykh sredstv: Stavropol: SKFU, 2016.
12. Milyukhina I. V., Karpenko M. N., Timofeeva A. A., Klimenko V. M., Scorometz A. A. The role of inflammation in the pathogenesis of Parkinson’s disease. Nevrologichesky zhurnal. – Neurological journal. 2013;3:5155.
13. Illarioshkin S. N. Modern view on etiology of Parkinson’s disease. Nevrologichesky zhurnal. – Neurological journal. 2015;20(4):413.
14. Lindholm D., Pham D. D., Cascone A., Eriksson O., Wennerberg K., Saarma M. c-Abl Inhibitors Enable Insights into the Pathophysiology and Neuroprotection in Parkinson’s Disease. Front. Aging Neurosci. 2016;8:254. https://doi.org/10.3389/fnagi.2016.00254
15. Stoker T. B., Torsney K. M., Barker R. A. Emerging Treatment Approaches for Parkinson’s Disease. Front. Neurosci. 2018;12:693. https://doi.org/10.3389/fnins.2018.00693

Keywords: 2-substituted derivatives of 3(h)-quinazolin-4-one, anticataleptic effect, haloperidol catalepsy